Oppenheimer Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX)

Oppenheimer reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report published on Friday morning, Benzinga reports. They currently have a $22.00 price target on the stock.

Other analysts also recently issued research reports about the company. Bank of America began coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a buy rating and a $24.00 price objective for the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Truist Financial initiated coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a buy rating and a $21.00 price target on the stock. Wedbush began coverage on shares of Perspective Therapeutics in a report on Tuesday, October 1st. They set an outperform rating and a $25.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating on the stock in a research note on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics has an average rating of Buy and an average price target of $21.43.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $12.28 on Friday. Perspective Therapeutics has a 1 year low of $2.20 and a 1 year high of $19.05. The business has a fifty day moving average of $13.83.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. On average, sell-side analysts anticipate that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Janus Henderson Group PLC bought a new position in Perspective Therapeutics in the 1st quarter worth approximately $15,511,000. Affinity Asset Advisors LLC acquired a new position in Perspective Therapeutics during the 1st quarter worth $6,069,000. Ally Bridge Group NY LLC bought a new position in Perspective Therapeutics in the 2nd quarter valued at $3,951,000. Finally, WealthPLAN Partners LLC acquired a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at $1,695,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.